Form 8-K

8-K — Maze Therapeutics, Inc.

Accession: 0001193125-26-354092

Filed: 2026-08-17

Period: 2026-08-13

CIK: 0001842295

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — d135740d8k.htm (Primary)

EX-99.1 (d135740dex991.htm)

GRAPHIC (g135740g0815092238007.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d135740d8k.htm · Sequence: 1

8-K

false 0001842295 0001842295 2026-08-13 2026-08-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2026

Maze Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-42490

82-2635018

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

171 Oyster Point Blvd., Suite 300

South San Francisco, California

94080

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 850-5070

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock - par value $0.001 per share

MAZE

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 13, 2026, the Board of Directors (the “Board”) of Maze Therapeutics, Inc. (the “Company”) appointed Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director, in each case effective August 13, 2026 (the “Appointment Date”). Dr. Johnson will serve as a Class III director for a term expiring at the Company’s 2028 annual meeting of stockholders, and Dr. Kornowski will serve as a Class I director for a term expiring at the Company’s 2029 annual meeting of stockholders, in each case until such director’s successor is duly elected and qualified, or until such director’s earlier death, resignation, disqualification, retirement or removal.

The Board appointed Dr. Johnson to serve as a member of the nominating and corporate governance committee of the Board, and appointed Dr. Kornowski to serve as a member of the audit committee and the compensation committee of the Board, in each case effective as of the Appointment Date.

Dr. Johnson, age 66, has served as the President of Wellesley College since 2016. Prior to that, Dr. Johnson founded and served as the inaugural Executive Director of the Connors Center for Women’s Health and Gender Biology at Brigham and Women’s Hospital, a Harvard teaching hospital, and as Chief of the Division of Women’s Health at Brigham and Women’s Hospital, in each case from July 2002 to June 2016. She also served as the Grayce A. Young Family Professor of Medicine in Women’s Health at Harvard Medical School and as a Professor of Epidemiology at the Harvard T.H. Chan School of Public Health. Dr. Johnson has served as a member of the board of directors of Johnson & Johnson, a multinational healthcare company, since 2023, as a member of the board of trustees of The Rockefeller University since November 2021, and as a member of the board of directors of the Isabella Stewart Gardner Museum since 2015. She is a member of the National Academy of Medicine and the American Academy of Arts and Sciences. Dr. Johnson received her A.B., her M.P.H. and her M.D. from Harvard University. Our Board believes Dr. Johnson’s is qualified to serve on our Board due to her extensive leadership experience in academic medicine, public health and higher education.

Dr. Kornowski, age 63, most recently served as Chief Executive Officer of Boston Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, from 2022 to 2025, and as a member of its board of directors. From 2018 to 2025, Dr. Kornowski served as a Senior Partner at Gurnet Point Capital, a healthcare-focused investment firm. Prior to that, Dr. Kornowski served as Executive Vice-President and Head of Roche Partnering at F. Hoffmann-La Roche AG, a multinational healthcare company, and as a member of its Extended Corporate Executive Committee, and served as a member of the board of directors of Chugai Pharmaceutical Co., Ltd. Dr. Kornowski received a Doctorate in Pharmacy from Paris Descartes University and an M.B.A. from the University of Chicago Booth School of Business. Our Board believes Dr. Kornowski’s is qualified to serve on our Board due to her extensive executive, investment and business development experience in the global biopharmaceutical industry.

In connection with their respective appointments as non-employee directors of the Company, each of Dr. Johnson and Dr. Kornowski will receive compensation in accordance with the Company’s non-employee director compensation policy (the “Director Compensation Policy”), including a pro rata portion of the $40,000 annual cash retainer for service as a director for the remaining portion of the year, together with the applicable committee retainers. In addition, in accordance with the Director Compensation Policy, the Board granted to each of Dr. Johnson and Dr. Kornowski, effective as of the Appointment Date, an option to purchase 36,000 shares of the Company’s common stock (each, an “Option Award”), with 1/36th of the shares underlying each Option Award vesting and becoming exercisable on each monthly anniversary of the Appointment Date, subject to the applicable director’s continued service to the Company.

Except as described above, there are no arrangements or understandings between either of Dr. Johnson or Dr. Kornowski and any other persons pursuant to which she was selected as a member of the Board. No family relationships exist between either of Dr. Johnson or Dr. Kornowski and any of the Company’s directors or executive officers. Neither Dr. Johnson nor Dr. Kornowski has any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Changes to the Classes of the Board.

In connection with the foregoing appointments, on August 13, 2026, the Board approved changes to the composition of the classes of the Board so that, as nearly as possible, each class consists of one-third of the total number of directors, as contemplated by the Company’s amended and restated certificate of incorporation. To effect these changes in accordance with the requirements of the Delaware General Corporation Law and the Company’s amended and restated certificate of incorporation, effective August 13, 2026, Nancy C. Andrews, M.D., Ph.D. resigned from her position as a Class III director (with a term expiring at the Company’s 2028 annual meeting of stockholders), subject to and conditioned upon her immediate reappointment as a Class II director, and the Board accepted Dr. Andrews’ resignation and immediately reappointed her as a Class II director with a term expiring at the Company’s 2027 annual meeting of stockholders. Also effective August 13, 2026, Hervé Hoppenot resigned from his position as a Class II director (with a term expiring at the Company’s 2027 annual meeting of stockholders), subject to and conditioned upon his immediate reappointment as a Class III director, and the Board accepted Mr. Hoppenot’s resignation and immediately reappointed him as a Class III director with a term expiring at the Company’s 2028 annual meeting of stockholders.

Item 7.01 Regulation FD Disclosure.

On August 13, 2026, the Company issued a press release announcing the appointment of Dr. Johnson and Dr. Kornowski to the Board. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Section 11 or 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act, whether made before or after the date hereof, except as expressly set forth by reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number

Description

99.1

Press release, dated August 13, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 17, 2026

By:

/s/ Courtney Phillips

Courtney Phillips

General Counsel and Corporate Secretary

EX-99.1

Filename: d135740dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Maze Therapeutics Announces Appointments to Its Board of Directors

August 13, 2026

Paula Johnson, M.D., M.P.H., and

Sophie Kornowski, Pharm.D., M.B.A., join Maze’s Board of Directors, adding to the Company’s deep bench of clinical and industry experience

SOUTH SAN

FRANCISCO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced

the appointments of Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., to its Board of Directors.

“We are excited to welcome Paula and

Sophie to our Board at this important time for our company. With key progress made in our development programs, we are looking ahead to several important milestones, including additional data from MZE829 in broad AMKD patients in late 2026 or early

2027, initial data from MZE782 in 2027, and additional trial initiations for both molecules next year,” said Jason Coloma, Ph.D., chief executive officer of Maze. “As we continue to advance Maze’s pipeline toward late-stage

clinical development and pre-commercial planning, both Paula and Sophie will bring a wealth of clinical and business experience to support our mission to harness the power of genetics to transform the lives of

patients.”

Dr. Johnson brings over 30 years of clinical and research experience, specializing in cardiology. She has served as President of Wellesley

College since 2016 and currently serves on the Board of Directors of Johnson & Johnson (J&J). Previously, Dr. Johnson founded and served as the inaugural Executive Director of the Connors Center for Women’s Health and Gender

Biology at Brigham and Women’s Hospital from 2002 to 2016, and served as the Chief of the Division of Women’s Health at Brigham and Women’s Hospital from 2002 to 2016. She previously served as a Clinical Epidemiologist at Brigham

and Women’s Hospital, as a Professor of Medicine at Harvard Medical School, and as Professor of Epidemiology at the Harvard School of Public Health. She holds an M.D. from Harvard Medical School, an M.P.H. from the Harvard T.H. Chan School of

Public Health, and an A.B. from Harvard.

Dr. Kornowski joins Maze’s Board of Directors with more than 35 years of biopharmaceutical leadership

experience, most recently serving as Chief Executive Officer of Boston Pharmaceuticals beginning in 2022, focusing the company’s pipeline on candidates for liver disease and leading the company to its acquisition by GlaxoSmithKline (GSK).

Previously, she served as a Senior Partner at Gurnet Point Capital. Dr. Kornowski was Executive Vice-President of Roche Partnering and a member of the Extended Corporate Executive Committee of F.

Hoffmann-La Roche AG and a board member of Chugai Pharmaceuticals. In that role, she led partnering and M&A strategy across early-stage compounds, late-stage assets, and technology-driven biotech

companies, working closely with R&D and Commercial teams at Roche and Genentech. Earlier in her career, she held several commercial leadership roles across geographies in leading innovative pharmaceutical and diagnostic companies in France,

Israel, and the U.S., notably at Roche and Merck & Co. She holds a Pharm.D. from Paris Descartes University and an M.B.A. from the University of Chicago Booth School of Business.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage

biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass™

platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or

best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and

MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow Maze on LinkedIn and X.

Forward-Looking Statements

This press release contains forward-looking

statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management. All statements other than

statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning the company’s future plans and prospects, any expectations regarding the safety or efficacy of

MZE829, MZE782 and other candidates under development, the ability of MZE829 to treat AMKD or other indications, the ability of MZE782 to treat PKU, CKD or other indications, the planned timing of the company’s clinical trials, data results

and further development of MZE829, MZE782 and other therapeutic candidates, and the company’s ability to advance its pipeline towards late-stage clinical development. In addition, when or if used in this press release, the words

“may,” “could,” “should,”

“anticipate,” “believe,” “estimate,” “expect,” “intend,”

“plan,” “will,” “predict” and similar expressions and their variants, as they relate to the company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances

of future performance. Although the company believes the expectations reflected in such forward-looking statements are reasonable, the company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual

results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the company’s forward-looking statements due to a variety of factors, including risks and uncertainties

related to the company’s ability to advance MZE829, MZE782 and its other therapeutic candidates, obtain regulatory approval of and ultimately commercialize the company’s therapeutic candidates, the timing and results of preclinical

studies and clinical trials, the company’s ability to fund development activities and achieve development goals, its ability to protect its intellectual property, general business and economic conditions, and risks related to the impact on its

business of macroeconomic conditions, including inflation, volatile interest rates, tariffs, instability in the global banking sector, and public health crises. Further information on potential risk factors that could affect the company’s

business and its financial results is detailed under the heading “Risk Factors” included in the documents the company files from time to time with the U.S. Securities and Exchange Commission, including the company’s Annual Report

on Form 10-K and Quarterly Reports on Form 10-Q. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. These

forward-looking statements speak only as of the date of this press release and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

IR/Corporate Contact:

Argot Partners

maze@argotpartners.com

Media Contact:

Amanda Lazaro, 1AB Media

amanda@1ABMedia.com

GRAPHIC

Filename: g135740g0815092238007.jpg · Sequence: 6

Binary file (4003 bytes)

Download g135740g0815092238007.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Document and Entity Information

Aug. 13, 2026

Cover [Abstract]

Amendment Flag

false

Entity Central Index Key

0001842295

Document Type

8-K

Document Period End Date

Aug. 13, 2026

Entity Registrant Name

Maze Therapeutics, Inc.

Entity Incorporation State Country Code

Entity File Number

001-42490

Entity Tax Identification Number

82-2635018

Entity Address, Address Line One

171 Oyster Point Blvd.

Entity Address, Address Line Two

Suite 300

Entity Address, City or Town

South San Francisco

Entity Address, State or Province

Entity Address, Postal Zip Code

94080

City Area Code

650

Local Phone Number

850-5070

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

Common Stock - par value $0.001 per share

Trading Symbol

MAZE

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Entity Ex Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration